Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments.
The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- Could you tell us a little about the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and their aims? (0:05)
- How many patients are enrolled to date and what data do you collect from them? (2:25)
- How are your data disseminated? (5:08)
- What are the future developments for ADNI? (6:38)
Disclosures: Michael Weiner receives support for his work from the following funding sources: NIH: 5U19AG024904-14; 1R01AG053798-01A1; R01 MH098062; U24 AG057437-01; 1U2CA060426-01; 1R01AG058676-01A1; and 1RF1AG059009-01, DOD: W81XWH-15-2-0070; 0W81XWH-12-2-0012; W81XWH-14-1-0462; W81XWH-13-1-0259, PCORI: PPRN-1501-26817, California Dept. of Public Health: 16-10054, U. Michigan: 18-PAF01312, Siemens: 444951-54249, Biogen: 174552, Hillblom Foundation: 2015-A-011-NET, Alzheimer’s Association: BHR-16-459161; The State of California: 18-109929; and also receives support from Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI-BHR), The Stroke Foundation, Fidelity Charitable, and the Veterans Administration.
Michael Weiner has served on Advisory Boards for Cerecin/Accera, Alzheon, Inc., Nestle/Nestec, PCORI/PPRN, Dolby Family Ventures, National Institute on Aging (NIA), Boston University Alzheimer’s Disease and CTE Center, MIRIADE at VUmc for Amsterdam UMC, Cytox, Indiana University, Acumen, Brain Health Registry and ADNI; and serves on the Editorial Boards for Alzheimer’s & Dementia, TMRI and MRI. He has provided consulting and/or acted as a speaker/lecturer to Cerecin/Accera, Inc., Alzheimer’s Drug Discovery Foundation (ADDF), BioClinica, The Buck Institute for Research on Aging, FUJIFILM-Toyama Chemical (Japan), Garfield Weston, Baird Equity Capital, University of Southern California (USC), T3D Therapeutics, Cytox, and Japanese Organization for Medical Device Development, Inc. (JOMDD); and holds stock options with Alzheon, Inc., Alzeca, and Anven.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
